Open access
Open access
Powered by Google Translator Translator

#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.

29 Aug, 2022 | 12:27h | UTC

Polypill Strategy in Secondary Cardiovascular Prevention – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Polypill reduces cardiovascular events in heart attack patients compared to usual care – European Society of Cardiology

Commentaries:

SECURE: Treatment With Polypill Significantly Lowers Risk of Major CV Events – American College of Cardiology

Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention – HCPLive

Related: M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention. (several studies on the subject)

 


Stay Updated in Your Specialty

No spam, just news.